Stephen C Schmechel
Overview
Explore the profile of Stephen C Schmechel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
733
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burton K, Mahen E, Konnick E, Blau S, Dorschner M, Ramirez A, et al.
JCO Precis Oncol
. 2022 Mar;
6:e2100280.
PMID: 35294224
Purpose: Patients with metastatic triple-negative breast cancer (mTNBC) have poor outcomes. The Intensive Trial of Omics in Cancer (ITOMIC) sought to determine the feasibility and potential efficacy of informing treatment...
2.
Deftereos G, Schmechel S, Waner E, Itani M, Dighe M, Tylee T
Diagn Cytopathol
. 2020 Apr;
48(7):610-617.
PMID: 32259404
Background: In the current version of The Bethesda System (TBS) for thyroid cytopathology, the atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) category has an estimated risk of malignancy...
3.
Leng E, Henriksen J, Rizzardi A, Jin J, Nam J, Brassuer B, et al.
Sci Rep
. 2019 May;
9(1):6992.
PMID: 31061447
Prostate cancer (PCa) is a major cause of cancer death among men. The histopathological examination of post-surgical prostate specimens and manual annotation of PCa not only allow for detailed assessment...
4.
Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors
Beckmann P, Larson J, Larsson A, Ostergaard J, Wagner S, Rahrmann E, et al.
Cancer Res
. 2019 Jan;
79(5):905-917.
PMID: 30674530
Medulloblastoma and central nervous system primitive neuroectodermal tumors (CNS-PNET) are aggressive, poorly differentiated brain tumors with limited effective therapies. Using () transposon mutagenesis, we identified novel genetic drivers of medulloblastoma...
5.
Seelig D, Ito D, Forster C, Yoon U, Breen M, Burns L, et al.
Leuk Lymphoma
. 2016 Dec;
58(7):1702-1710.
PMID: 27931134
Activation of the classical nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway is a common molecular event observed in both human and canine diffuse large B-cell lymphoma (DLBCL). Although...
6.
Rizzardi A, Zhang X, Vogel R, Kolb S, Geybels M, Leung Y, et al.
Diagn Pathol
. 2016 Jul;
11(1):63.
PMID: 27401406
Background: Digital image analysis offers advantages over traditional pathologist visual scoring of immunohistochemistry, although few studies examining the correlation and reproducibility of these methods have been performed in prostate cancer....
7.
Metzger G, Kalavagunta C, Spilseth B, Bolan P, Li X, Hutter D, et al.
Radiology
. 2016 Jan;
279(3):805-16.
PMID: 26761720
Purpose To develop multiparametric magnetic resonance (MR) imaging models to generate a quantitative, user-independent, voxel-wise composite biomarker score (CBS) for detection of prostate cancer by using coregistered correlative histopathologic results,...
8.
Blau C, Ramirez A, Blau S, Pritchard C, Dorschner M, Schmechel S, et al.
J Natl Compr Canc Netw
. 2016 Jan;
14(1):8-17.
PMID: 26733551
Accelerating cancer research is expected to require new types of clinical trials. This report describes the Intensive Trial of OMics in Cancer (ITOMIC) and a participant with triple-negative breast cancer...
9.
Rahrmann E, Moriarity B, Otto G, Watson A, Choi K, Collins M, et al.
Am J Pathol
. 2014 May;
184(7):2082-98.
PMID: 24832557
Malignant peripheral nerve sheath tumors (MPNSTs) are genetically diverse, aggressive sarcomas that occur sporadically or in association with neurofibromatosis type 1 syndrome. Reduced TP53 gene expression and amplification/overexpression of the...
10.
Rizzardi A, Rosener N, Koopmeiners J, Vogel R, Metzger G, Forster C, et al.
BMC Cancer
. 2014 Apr;
14:244.
PMID: 24708576
Background: Prognostic multibiomarker signatures in prostate cancer (PCa) may improve patient management and provide a bridge for developing novel therapeutics and imaging methods. Our objective was to evaluate the association...